Adverse events Grade 3 oesophagitis, diarrhoea and nausea · adults with metastatic extradural spinal cord compression (poor prognosis, no spinal instability or bony impingement of cord)
Split‐course radiotherapy (8 fractions, 30 Gy) showed no clear difference in adverse events Grade 3 oesophagitis, diarrhoea, and nausea compared with short‐course radiotherapy (2 fractions, 16 Gy) (moderate certainty).
1 finding from 1 review
Quality of life · adults with metastatic extradural spinal cord compression (poor prognosis, no spinal instability or bony impingement of cord)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ambulation · adults with metastatic extradural spinal cord compression (poor prognosis, no spinal instability or bony impingement of cord)
Split‐course radiotherapy (8 fractions, 30 Gy) showed no clear difference in ambulation One month after treatment compared with short‐course radiotherapy (2 fractions, 16 Gy) (moderate certainty).
1 finding from 1 review
Survival · adults with metastatic extradural spinal cord compression (poor prognosis, no spinal instability or bony impingement of cord)
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · adults with chronic pain
1 finding from 1 review
Disability (0 to < 1 week postintervention) measured using self‐reported disability/pain interference scales · adults with chronic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · adults with chronic pain
1 finding from 1 review
Number of patients in arm satisfied with therapy · patients with postoperative pain
1 finding from 1 review
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
rolapitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
rolapitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
aprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
netupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
aprepitant + ramosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
fosaprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review
fosnetupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
1 finding from 1 review